Novavax (NVAX) Liabilities and Shareholders Equity (2010 - 2026)

Novavax's Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $1.0 billion for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 19.32% year-over-year to $1.0 billion; the TTM figure through Mar 2026 stood at $4.7 billion (down 25.82% YoY), while the FY2025 annual figure was $1.2 billion, down 24.6% from the prior year.
• Liabilities and Shareholders Equity was $1.0 billion for Q1 2026 at Novavax, down from $1.2 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $2.8 billion in Q1 2022 to a low of $1.0 billion in Q1 2026.
• Historically, Liabilities and Shareholders Equity has averaged $1.7 billion across 5 years, with a median of $1.7 billion in 2023.
• The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity increased 8.68% in 2022, then sank 45.58% in 2023.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $2.3 billion in 2022, then declined by 20.42% to $1.8 billion in 2023, then fell by 13.19% to $1.6 billion in 2024, then slipped by 24.6% to $1.2 billion in 2025, then decreased by 11.33% to $1.0 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $1.0 billion (Q1 2026), $1.2 billion (Q4 2025), and $1.2 billion (Q3 2025), per Business Quant data.